Now, AI technology can help in early detection of diseases like arthritis and lupus. | Health News | Patrika News ...

A German research team’s discoveries about autoimmune diseases are opening up new possibilities for patients with lupus and ...

Patients with SLE have a higher prevalence of primary headaches vs those with RA or pSS, but similar percentages were found when comparing healthy controls.

Cullinan offers promising oncology and autoimmune products, strong financials, and potential for growth, making it a ...

IGM Biosciences (IGMS) is slashing its workforce by 73% and discontinuing development of two of its lead drug candidates in ...

Conflict around gray wolves has become so hostile, the U.S. government hired a mediator. Her task is a difficult one.

Spain boasts diverse ecosystems, home to unique wildlife like the Iberian wolf. Once widespread across Europe, the Iberian ...

IGM Biosciences (IGMS) announced a strategic update to halt further development of imvotamab, an IgM-based CD20 X CD3 bispecific antibody T ...

The company is currently evaluating internal options as well as potential strategic alternatives with the goal of maximizing value for its shareholders. The company also announced that it is reducing ...

The biotech will stop developing two drugs and lay off nearly three-quarters of its staff after its lead therapy wasn’t as potent in early testing as the company expected.

IGM Biosciences is again cutting staff as it scraps an autoimmune-drug trial after failing to achieve the desired results.

Company halting further development of imvotamab (CD20 x CD3) and IGM-2644 (CD38 x CD3) – – Company reducing its workforce by 73% – – Cash and investments of $183.8 million (unaudited) as of December ...